Early Chronic Fluoxetine Treatment of Ts65Dn Mice Rescues Synaptic Vesicular Deficits and Prevents Aberrant Proteomic Alterations

S. Hossein Fatemi,Elysabeth D. Otte,Timothy D. Folsom,Arthur C. Eschenlauer,Randall J. Roper,Justin W. Aman,Paul D. Thuras

DOI: https://doi.org/10.3390/genes15040452

IF: 4.141

2024-04-04

Genes

Abstract:Down syndrome (DS) is the most common form of inherited intellectual disability caused by trisomy of chromosome 21, presenting with intellectual impairment, craniofacial abnormalities, cardiac defects, and gastrointestinal disorders. The Ts65Dn mouse model replicates many abnormalities of DS. We hypothesized that investigation of the cerebral cortex of fluoxetine-treated trisomic mice may provide proteomic signatures that identify therapeutic targets for DS. Subcellular fractionation of synaptosomes from cerebral cortices of age- and brain-area-matched samples from fluoxetine-treated vs. water-treated trisomic and euploid male mice were subjected to HPLC-tandem mass spectrometry. Analysis of the data revealed enrichment of trisomic risk genes that participate in regulation of synaptic vesicular traffic, pre-synaptic and post-synaptic development, and mitochondrial energy pathways during early brain development. Proteomic analysis of trisomic synaptic fractions revealed significant downregulation of proteins involved in synaptic vesicular traffic, including vesicular endocytosis (CLTA, CLTB, CLTC), synaptic assembly and maturation (EXOC1, EXOC3, EXOC8), anterograde axonal transport (EXOC1), neurotransmitter transport to PSD (SACM1L), endosomal-lysosomal acidification (ROGDI, DMXL2), and synaptic signaling (NRXN1, HIP1, ITSN1, YWHAG). Additionally, trisomic proteomes revealed upregulation of several trafficking proteins, involved in vesicular exocytosis (Rab5B), synapse elimination (UBE3A), scission of endocytosis (DBN1), transport of ER in dendritic spines (MYO5A), presynaptic activity-dependent bulk endocytosis (FMR1), and NMDA receptor activity (GRIN2A). Chronic fluoxetine treatment of Ts65Dn mice rescued synaptic vesicular abnormalities and prevented abnormal proteomic changes in adult Ts65Dn mice, pointing to therapeutic targets for potential treatment of DS.

genetics & heredity

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify possible therapeutic targets to improve the symptoms of Down syndrome patients by studying the effects of fluoxetine (a selective serotonin reuptake inhibitor) on synaptic vesicle defects and proteomic abnormalities in the cerebral cortex of Ts65Dn mice (an animal model of Down syndrome).

Specifically, the authors hypothesized that through proteomic analysis of the cerebral cortex of trisomic mice treated with fluoxetine, the enrichment of trisomic risk genes related to synaptic vesicle transport, pre - and post - synaptic development, and mitochondrial energy pathways could be found. These changes are especially important during early brain development. In addition, the authors also explored whether chronic fluoxetine treatment could correct synaptic vesicle abnormalities in Ts65Dn mice and prevent abnormal proteomic changes in adult Ts65Dn mice, thus providing clues for the potential treatment of Down syndrome.

### Main research questions:
1. **Can proteomic biomarkers that cause endocytic transport dysfunction in trisomic mice be identified?**
2. **Can fluoxetine correct intracellular defects in trisomic mice?**
3. **Can long - term administration of fluoxetine correct brain dysfunction in trisomic mice before the critical period of brain and sexual maturation?**

### Research background:
- **Down syndrome (DS)**: Caused by trisomy of chromosome 21, and is manifested by multiple symptoms such as intellectual disability, craniofacial malformations, heart defects and gastrointestinal diseases.
- **Ts65Dn mouse model**: Widely used to study the neurodevelopment and phenotypic characteristics of Down syndrome, showing multiple abnormalities similar to human DS, such as delayed motor skills, cognitive impairment, etc.
- **The role of fluoxetine**: Previous studies have shown that fluoxetine can improve the anatomical, electrophysiological and cognitive deficits in TS65Dn mice.

### Research methods:
- **Animal model**: Ts65Dn mice and normal diploid mice were used.
- **Drug treatment**: Starting from the 28th day after birth, mice were given 0.04 mg/mL fluoxetine aqueous solution or ordinary water until the 88th day.
- **Proteomic analysis**: Quantitative analysis of synaptic proteins in the cerebral cortex was carried out by subcellular fractionation and liquid chromatography - tandem mass spectrometry (LC - MS/MS) techniques.

### Expected results:
- **Identify proteomic changes related to synaptic vesicle transport and synaptic function**.
- **Verify whether fluoxetine can correct these proteomic abnormalities**.
- **Explore the therapeutic effect of fluoxetine during the critical development period**.

Through these studies, the authors hope to provide new biological mechanisms and potential therapeutic targets for the treatment of Down syndrome.